Waldenstrom Macroglobulinemia clinical trials at UC Cancer
1 research study open to new patients

• Safety, PK, PD, and Antitumor Activity of SNS-062 (Vecabrutinib) in B Lymphoid Cancers

  open to eligible people ages 18 years and up

  Phase 1b (Dose Escalation) in primarily CLL/SLL patients will evaluate safety and pharmacology of self-administered twice a day oral doses beginning at 25 mg/dose for 4 weeks with succeeding cohorts at escalating doses until establishing dose limiting toxicity or, recommended Phase 2 dose. Patient data will be assessed before authorizing dose escalation cohorts. Phase 2 (Cohort Expansion) will follow in cohorts using the recommended dose to explore clinical activity, safety, pharmacology of SNS-062 (vecabrutinib) as monotherapy.

  at UC Irvine UCSD

Last updated: March 12, 2019